HC Wainwright Reiterates “Buy” Rating for Replimune Group (NASDAQ:REPL)

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report published on Friday morning,Benzinga reports. They currently have a $17.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group currently has a consensus rating of “Buy” and a consensus price target of $17.00.

Replimune Group Trading Up 35.1 %

NASDAQ:REPL opened at $14.93 on Friday. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm has a market cap of $1.02 billion, a P/E ratio of -4.90 and a beta of 1.19. The firm has a 50-day simple moving average of $11.59 and a 200-day simple moving average of $9.74.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities analysts anticipate that Replimune Group will post -3.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently added to or reduced their stakes in REPL. Nisa Investment Advisors LLC raised its position in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group during the second quarter worth $57,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group during the second quarter worth $108,000. Quest Partners LLC grew its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the third quarter worth $133,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.